How many drugs treat Non-allergic asthma?

Drug Landscape tracks 9 marketed treatments for Non-allergic asthma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/non-allergic-asthma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Non-allergic asthma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-allergic asthma (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Non-allergic asthma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Foradil	FORMOTEROL	Novartis	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2001-01-01
Singulair	montelukast	Merck & Co.	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Elocon	MOMETASONE FUROATE	Merck & Co.	Corticosteroid	Progesterone receptor	1987-01-01
Nasonex	Nasonex	University of Alberta		Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor
Flixotide	Flixotide	Mundipharma Research Limited		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Fluticason	Fluticason	Creighton University		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Serevent	Serevent	Fundacio Privada Mon Clinic Barcelona		Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Singulair	Singulair	Genuine Research Center, Egypt		Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 2 drugs in Non-allergic asthma
Creighton University · 1 drug in Non-allergic asthma
Fundacio Privada Mon Clinic Barcelona · 1 drug in Non-allergic asthma
GSK (GlaxoSmithKline) · 1 drug in Non-allergic asthma
Genuine Research Center, Egypt · 1 drug in Non-allergic asthma
Mundipharma Research Limited · 1 drug in Non-allergic asthma
Novartis · 1 drug in Non-allergic asthma
Teva Pharm · 1 drug in Non-allergic asthma
· 1 drug in Non-allergic asthma
University of Alberta · 1 drug in Non-allergic asthma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Non-allergic asthma:

Cite this brief

Drug Landscape (2026). Non-allergic asthma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-allergic-asthma. Accessed 2026-06-10.

Non-allergic asthma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing